Why is levothyroxine treated as neutral by underwriters?
Levothyroxine is a synthetic hormone replacement that brings thyroid levels back to normal range. When it is working as intended and TSH levels are stable, there is no elevated mortality risk for the underwriter to price. The medication is not managing a deteriorating condition. It is replacing a hormone the body no longer produces in sufficient quantity. A stable thyroid level on a consistent dose of levothyroxine looks, to an underwriter, like a managed and resolved condition.
This is why levothyroxine does not appear as a flag in the simplified issue medication picture the way a cardiac medication or an immunosuppressant might. It is among the most commonly dispensed medications in Canada. Carriers know it well. A long-term, stable levothyroxine prescription is not a concern, and a recent dosage adjustment for a TSH that drifted slightly is captured by the medication-change question but at the most modest level. A thyroid dosage tweak looks very different to an underwriter than a new cardiac drug or a new biologic.
Hypothyroidism on stable levothyroxine is one of the most accessible health profiles in the simplified issue market. Most applicants in this situation have access to the full range of term and permanent coverage at standard rates. A licensed advisor familiar with the no-exam market can confirm the outcome before any application is submitted.
Is hyperthyroidism or Graves' disease assessed differently?
Hyperthyroidism, including Graves' disease, is assessed the same way as hypothyroidism in the simplified issue question set. Both fall under the thyroid disease category at the pass/fail gate level, which affects best-rate access but does not restrict term or permanent coverage. Someone who had Graves' disease, received treatment, and has been stable since is in a position very similar to someone managing hypothyroidism with levothyroxine.
The one area where hyperthyroidism creates additional complexity is cardiovascular. Untreated or undertreated hyperthyroidism can produce AFib and other cardiac rhythm problems. If a cardiac condition developed alongside or following a hyperthyroidism diagnosis, that cardiac condition is assessed independently under the cardiac question set, on its own timing. The thyroid history is context. The cardiac question governs its own outcome.
How does a thyroid cancer history change what's available?
This is the part of the article that matters most for a meaningful portion of readers, and the part that no competing page handles clearly.
A thyroid cancer history is not assessed under the thyroid disease question. It is assessed under the cancer question set. These are different questions with different outcomes, and the distinction matters significantly.
Thyroid cancer is one of the most survivable cancers in Canada. Papillary thyroid cancer and follicular thyroid cancer, the most common types, have very high long-term survival rates when treated early. The cancer survivor article on this site covers how the cancer timing framework works in detail, but the summary is: well beyond treatment completion, with a stable recovery and no recurrence, both term and permanent coverage are typically available. The thyroid cancer history shifts the outcome from the straightforward thyroid disease picture to the cancer timing framework, which is more complex but far from a closed door for survivors who are years past treatment.
If a thyroid cancer history is part of the picture, the cancer question, not the thyroid disease question, is what governs the application. The outcome depends on the cancer type, when treatment ended, and whether there has been any recurrence. A licensed advisor should know this history before any application is submitted, because the right carrier and product for a thyroid cancer survivor may be different from what a straightforward hypothyroidism applicant needs.
Anaplastic thyroid cancer, which is rare and aggressive, produces a different outcome from the well-differentiated types. If the cancer type is unclear or the applicant is unsure which category applies, a licensed advisor can help identify how the specific history is likely to be assessed before an application goes in.
How is Hashimoto's thyroiditis treated on a life insurance application?
Hashimoto's thyroiditis, the autoimmune condition that is the most common cause of hypothyroidism in Canada, is assessed as part of the thyroid disease category rather than the autoimmune or immune system question. This is worth knowing because the immune system question captures conditions like rheumatoid arthritis that require treatment beyond anti-inflammatories. Hashimoto's, even though it is autoimmune in origin, is not captured there. It sits with the thyroid conditions, and the outcome for a Hashimoto's patient on stable levothyroxine is the same as for any other well-managed hypothyroidism patient: essentially no restriction.
What to Bring to the Conversation
Know your current thyroid medication and how long the prescription has been stable. Know whether any thyroid cancer has ever been diagnosed and if so, when it was treated and what type it was. Know whether any cardiac conditions, including AFib, have developed alongside the thyroid history.
Know the monthly premium that is genuinely comfortable to sustain. Know the obligations a death would leave behind: a mortgage, income a spouse depends on, final expenses. Coverage amount follows from that picture.
For most Canadians managing thyroid disease with stable medication, the conversation produces a better answer than the one they assumed before they started. The condition that occasionally changes things is a different diagnosis entirely.
This article is for educational purposes only and does not constitute insurance advice. Eligibility, premiums, and coverage terms vary by individual health profile and insurer. Speak with a licensed Canadian insurance advisor before making any coverage decision. Reviewed by a licensed Canadian insurance professional.